The week of July 13, 2026, US Defense Secretary Pete Hegseth ordered annual testosterone-deficiency screening for active-duty and reserve service members aged 30 and older, framing it as a move to bolster military "readiness and performance." Within days, the directive drew sharp pushback: five of six men's-health experts contacted by Reuters said they were puzzled by the announcement and worried it could lead to unnecessary — or even harmful — treatment, according to coverage carried by Reuters, The Straits Times, Newsweek and Firstpost.

Why It Matters

The military is one of the largest single healthcare systems in the US, and a blanket testosterone-screening mandate for its 30-plus population could shift cultural and clinical norms far beyond the barracks — feeding directly into the booming TRT telehealth market. But the near-unanimous expert skepticism underscores the industry's core tension: destigmatized access to men's hormone therapy versus evidence-based prescribing. How the Pentagon handles "abnormal" results will be a real-world stress test of where that line sits.

The clinical objection is that routine population-wide testosterone screening of otherwise healthy men isn't supported by major urology or endocrinology guidelines, which reserve testing for men with actual symptoms of hypogonadism. Physicians warned that flagging "low" numbers in asymptomatic troops could push service members toward testosterone replacement therapy (TRT) they don't need — raising risks including infertility, and inviting inappropriate anabolic use. The Pentagon has not published detailed guidance on how abnormal results will be evaluated, or whether screening will apply equally to men and women. Hegseth said testing would come with advice to help members make treatment decisions, and that any treatment would be voluntary.

The order fits a pattern of contested health-policy moves from the current administration's defense and health leadership — the same reporting noted Hegseth's earlier reversal of the military flu-vaccine mandate (walked back after an outbreak) and HHS's removal of 17 members from a vaccine advisory panel. Critics see the testosterone mandate as part of a broader "masculinity and performance" framing of military fitness rather than an evidence-driven screening program.

For the sexual-health industry, the directive is a curious macro signal. It arrives as the FDA separately opens pathways toward approved testosterone indications for low libido and weighs descheduling testosterone, and as telehealth players (Hims, LifeMD's XYOSTED deal, Marius's Kyzatrex) race to expand TRT access. A government-mandated screening cohort of hundreds of thousands of men over 30 could normalize testosterone testing broadly — or, if it produces a wave of questionable prescriptions, become a cautionary tale about over-medicalizing "low-T."

Sources

Update — 2026-07-19

{Initial entry — story first created.}